We will be contrasting the differences between Trillium Therapeutics Inc. (NASDAQ:TRIL) and Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM) as far as profitability, analyst recommendations, institutional ownership, risk, dividends, earnings and valuation are concerned. The two businesses are rivals in the Biotechnology industry.

Valuation & Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Trillium Therapeutics Inc.	N/A	0.00	N/A	-2.55	0.00
Bellicum Pharmaceuticals Inc.	1.12M	134.54	98.04M	-2.47	0.00

Table 1 shows top-line revenue, earnings per share (EPS) and valuation of the two companies.

Profitability

Table 2 represents Trillium Therapeutics Inc. (NASDAQ:TRIL) and Bellicum Pharmaceuticals Inc. (NASDAQ:BLCM)’s return on equity, net margins and return on assets.

	Net Margins	Return on Equity	Return on Assets
Trillium Therapeutics Inc.	0.00%	0%	0%
Bellicum Pharmaceuticals Inc.	-8,753.57%	0%	0%

Analyst Ratings

Trillium Therapeutics Inc. and Bellicum Pharmaceuticals Inc. Recommendations and Ratings are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Trillium Therapeutics Inc.	0	1	1	2.50
Bellicum Pharmaceuticals Inc.	0	0	0	0.00

$2.5 is Trillium Therapeutics Inc.’s average target price while its potential upside is 262.37%.

Insider and Institutional Ownership

Institutional investors held 39.41% of Trillium Therapeutics Inc. shares and 55.4% of Bellicum Pharmaceuticals Inc. shares. Insiders held 0.37% of Trillium Therapeutics Inc. shares. Insiders Comparatively, held 0.4% of Bellicum Pharmaceuticals Inc. shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Trillium Therapeutics Inc.	-5.61%	-61.62%	-75.2%	-88.07%	-90.46%	-59.53%
Bellicum Pharmaceuticals Inc.	-5.04%	-3.03%	-24.88%	-54.42%	-54.42%	9.59%

For the past year Trillium Therapeutics Inc. had bearish trend while Bellicum Pharmaceuticals Inc. had bullish trend.

Summary

Bellicum Pharmaceuticals Inc. beats on 5 of the 8 factors Trillium Therapeutics Inc.

Trillium Therapeutics Inc., a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The companyÂ’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy. Its product candidates also include TTI-622, an IgG4 SIRPaFc protein for combination therapy; bromodomain inhibitor; and epidermal growth factor receptor antagonist, which are in preclinical development stage, as well as undisclosed immuno-oncology targets that are in the discovery Phase. The company was formerly known as Stem Cell Therapeutics Corp. and changed its name to Trillium Therapeutics Inc. in June 2014. Trillium Therapeutics Inc. was founded in 2004 and is headquartered in Mississauga, Canada.

Bellicum Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. Its clinical product candidate is BPX-501, an adjunct T-cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation. The company’s preclinical product candidates include BPX-601, a GoCAR-T product candidate for treating solid tumors expressing the prostate stem cell antigen; and BPX-701, a T cell receptors (TCR) product candidate for the treatment of solid tumors expressing the preferentially-expressed antigen in melanoma. It has a collaboration agreement with Adaptimmune Therapeutics plc to evaluate, develop, and commercialize T-cell therapies; Ospedale Pediatrico Bambino Gesú for the design and development of various T cell immunotherapies; and Academisch Ziekenhuis Leiden for research to discover and validate high-affinity TCR product candidates targeting various cancer-associated antigens. Bellicum Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Houston, Texas.